Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Other Gross PP&E Adjustments (2021 - 2025)

Amylyx Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 5 years, most recently at -$7.5 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$7.5 million for Q4 2025, down 164.77% from a year ago — trailing twelve months through Dec 2025 was -$7.5 million (down 164.77% YoY), and the annual figure for FY2025 was -$7.5 million, down 164.77%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$7.5 million at Amylyx Pharmaceuticals, down from -$5.5 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for AMLX hit a ceiling of $527000.0 in Q4 2021 and a floor of -$7.5 million in Q4 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$4.6 million (2023), compared with a mean of -$4.3 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: crashed 892.6% in 2022 and later soared 61.38% in 2025.
  • Amylyx Pharmaceuticals' Other Gross PP&E Adjustments stood at $527000.0 in 2021, then crashed by 892.6% to -$4.2 million in 2022, then rose by 23.32% to -$3.2 million in 2023, then grew by 11.11% to -$2.8 million in 2024, then tumbled by 164.77% to -$7.5 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$7.5 million (Q4 2025), -$5.5 million (Q3 2025), and -$5.8 million (Q2 2025) per Business Quant data.